GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress
30 Novembro 2023 - 6:30PM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced the
presentation of data from recent preclinical studies of its vaccine
candidates against Marburg virus and Sudan virus.
The data were presented during the World Vaccine
Congress, West Coast conference, being held in Santa Clara, CA from
November 27-30, 2023. The presentation, titled “Design and
evaluation of vaccines against hemorrhagic fevers using the MVA-VLP
platform,” was delivered by Jason Comer, Ph.D., Associate
Professor, Department of Microbiology and Immunology, University of
Texas Medical Branch at Galveston (UTMB).
Mark Newman, Ph.D., GeoVax Chief Scientific
Officer, commented, “We are highly encouraged by the results of
these studies of our MARV vaccine candidate. It is also important
to note that, by virtue of the MVA vector utilized in the design of
this vaccine, it also provides the potential to protect against
Mpox (“Monkeypox”), which is critically important in many regions
of the world where MARV and other Ebola outbreaks occur.”
In this presentation, Dr. Comer discussed UTMB’s
services for regulated, nonclinical studies, and he presented
information about the Filoviridae family of viruses which include,
among others, Ebola virus (EBOV), Sudan virus (SUDV) and Marburg
virus (MARV). In his talk, Dr. Comer reviewed the preclinical
efficacy studies of GeoVax’s vaccine candidates for SUDV and MARV,
which were contracted to UTMB through the National Institute of
Allergy and Infectious Disease (NIAID) Preclinical Services.
Of particular interest, immunization with
GeoVax’s MARV vaccine candidate (MVA-VLP-MARV) conferred 80%
survival in cynomolgus macaques following a challenge with a lethal
dose of MARV. Vaccination protected nonhuman primates from viremia,
weight loss and death. Evaluation of immune responses following
vaccination demonstrated the presence of both neutralizing
antibodies and functional T cells, indicating a breadth of
responses that combine for optimal protection.
The work conducted by UTMB built upon earlier
studies demonstrating that guinea pigs vaccinated with MVA-VLP-MARV
were 100% protected against death and disease caused by the Angola
strain of MARV. The vaccine induced immune responses were
characterized by MARV-specific binding and neutralizing antibodies
as well as other effector functions like antibody-dependent
phagocytosis. The Angola strain is the most virulent strain of MARV
characterized by a fatality rate of up to 90% in humans.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing novel therapies and vaccines for
solid tumor cancers and many of the world’s most threatening
infectious diseases. The company’s lead program in oncology is a
novel oncolytic solid tumor gene-directed therapy, Gedeptin®,
presently in a multicenter Phase 1/2 clinical trial for advanced
head and neck cancers. GeoVax’s lead infectious disease candidate
is GEO-CM04S1, a next-generation COVID-19 vaccine targeting
high-risk immunocompromised patient populations. Currently in three
Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary
vaccine for immunocompromised patients such as those suffering from
hematologic cancers and other patient populations for whom the
current authorized COVID-19 vaccines are insufficient, and as a
booster vaccine in patients with chronic lymphocytic leukemia
(CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial
evaluating the vaccine as a more robust, durable COVID-19 booster
among healthy patients who previously received the mRNA vaccines.
GeoVax has a leadership team who have driven significant value
creation across multiple life science companies over the past
several decades. For more information, visit our website:
www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements
regarding GeoVax’s business plans. The words “believe,” “look
forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “could,” “target,” “potential,” “is likely,”
“will,” “expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is
contained in our periodic reports on Form 10-Q and Form 10-K that
we have filed and will file with the SEC. Any forward-looking
statement made by us herein speaks only as of the date on which it
is made. Factors or events that could cause our actual results to
differ may emerge from time to time, and it is not possible for us
to predict all of them. We undertake no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law.
Company Contact: |
|
Investor Relations Contact: |
|
Media Contact: |
info@geovax.com |
|
paige.kelly@sternir.com |
|
sr@roberts-communications.com |
678-384-7220 |
|
212-698-8699 |
|
202-779-0929 |
|
|
|
|
|
GeoVax Labs (NASDAQ:GOVXW)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
GeoVax Labs (NASDAQ:GOVXW)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024